LifeScan Scotland Ltd, Inverness, UK.
LifeScan Global Corporation, Malvern, PA, USA.
J Diabetes Sci Technol. 2024 Sep;18(5):1087-1095. doi: 10.1177/19322968221148764. Epub 2023 Jan 30.
The OneTouch Verio Flex® (OTVF) blood glucose (BG) meter features a ColorSure® Range Indicator. Diabetes management is enhanced by connecting the meter to the OneTouch Reveal® (OTR) mobile app. We sought to provide real-world evidence (RWE) that combining both devices improves glycemic control.
Anonymized glucose and app analytics were extracted from a server from over 144 000 people with diabetes (PWDs). Data from their first 14 days using OTVF and OTR were compared with 14 days prior to 90- and 180-day timepoints using paired within-subject differences.
In people with type 1 diabetes (PwT1D) or people with type 2 diabetes (PwT2D), readings in-range (RIR) improved by +6.1 (54.5% to 60.6%) and +11.9 percentage points (68.2% to 80.1%), respectively, over 180 days, and hyperglycemia was reduced by -6.6 (40.5% to 33.9%) and -12.0 (30.3% to 18.3%). In total, 35% of PwT1D and 40% of PwT2D improved RIR by >10 percentage points. People with type 1 diabetes spending two to four sessions or 10 to 20 minutes per week on the app improved RIR by +5.1 and 7.0, respectively. People with type 2 diabetes spending two to four sessions or 10 to 20 minutes per week on the app improved RIR by +11.6 and 12.0, respectively. In PwT1D or PwT2D, mean BG reduced by -11.4 and -19.5 mg/dL, respectively, from baseline to 180 days, with no clinically meaningful changes in percentage of hypoglycemic readings. All glycemic changes were statistically significant ( < .0005 level).
Real-world data from over 144 000 PWDs demonstrated improved percentage readings in-range and reduced hyperglycemia in PWDs using the OneTouch Verio Flex blood glucose meter and OneTouch Reveal app.
OneTouch Verio Flex®（OTVF）血糖仪具有 ColorSure®Range Indicator。通过将血糖仪与 OneTouch Reveal®（OTR）移动应用程序连接，可以增强糖尿病管理。我们旨在提供真实世界证据（RWE），证明结合这两种设备可以改善血糖控制。
从超过 144000 名糖尿病患者（PWD）的服务器中提取匿名血糖和应用程序分析数据。将他们使用 OTVF 和 OTR 的前 14 天的数据与使用配对的个体内差异的 90 天和 180 天时间点的前 14 天数据进行比较。
在 1 型糖尿病患者（PwT1D）或 2 型糖尿病患者（PwT2D）中，在 180 天内，范围内读数（RIR）分别提高了+6.1（54.5%至 60.6%）和+11.9 个百分点（68.2%至 80.1%），并且高血糖分别降低了-6.6（40.5%至 33.9%）和-12.0（30.3%至 18.3%）。在总共 35%的 PwT1D 和 40%的 PwT2D 中，RIR 提高了>10 个百分点。每周在应用程序上花费两到四个会话或 10 到 20 分钟的 1 型糖尿病患者，RIR 分别提高了+5.1 和+7.0。每周在应用程序上花费两到四个会话或 10 到 20 分钟的 2 型糖尿病患者，RIR 分别提高了+11.6 和+12.0。在 PwT1D 或 PwT2D 中，平均血糖分别从基线下降了-11.4 和-19.5mg/dL，到 180 天，低血糖读数的百分比没有明显变化。所有血糖变化均具有统计学意义（<.0005 水平）。
来自超过 144000 名 PWD 的真实世界数据表明，使用 OneTouch Verio Flex 血糖仪和 OneTouch Reveal 应用程序的 PWD 中，范围内读数百分比提高，高血糖减少。
